This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
According to a recent GlobalData report, healthcare professionals have – for the second year in a row – ranked artificial intelligence (AI) and BigData as the top two technologies revolutionising the pharmaceutical sector. The legacy of this disruption has been a rethink in the way pharmacompanies do business.
Time is also of the essence in drug development, as competitive product-to-market lead times help pharmacompanies improve profitability. With the advancement in digital technologies, data collection from end-users enables pharmacompanies to take notice of certain trends.
They had to be nurtured and cared for, despite the fact we, as pharmacompanies, have very limited direct access to patients. Historically, marketing excellence has been very product-driven. We need to love our customers more than our products and place their safety and interests above everything else.
Moreover, the adoption of digital tools like mobile apps and telemedicine platforms is facilitating direct communication between pharmacompanies and end-users. As patients become more digitally savvy, pharmacompanies are investing in creating seamless digital experiences that cater to their needs and preferences.
The ‘PEP Talks’ monthly e-newsletter has approaching 50 pharmacompanies as subscribers and the inaugural ‘Patient Engagement Day’ on September 01 st achieved an inspirational number of downloads of toolkits for ways to ‘Amplify the Patient Voice’ as the launch theme. Will pharma listen, and is this even their role to do so?
. “The goal is to look at the primary endpoints of pain intensity and pain interference, but we’re also looking to fill in additional clinical and health economic gaps to understand the true value of our product within healthcare,” Sackman explains.
Understanding the Shifts in the Pharma Landscape The pharmaceutical landscape is experiencing significant shifts, primarily due to advancements in technology and the increasing digitization of healthcare. Content marketing is another powerful tool in the pharma marketer’s arsenal.
But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharmacompanies in the world: AstraZeneca.
MM&M covers the news and happenings in the agency world and pharma marketing world Med Ad News focused on the agency side and a lot of great awards. PM360 is the go-to when it comes to the product manager and the, how-to manual, if you will, for product managers. BigData was a critical topic.
It has been quick to give reassurance that any analysis of patient data will comply with the EU’s data protection requirements. “Access to raw data can assist regulators in understanding the submitted evidence and therefore inform the regulatory decisions on the benefit-risk balance of the product,” it continues.
Bigdata analysis can be enormously powerful in providing insights for business strategy throughout the pharma value chain, including in the acceleration of drug discovery and development, optimization of manufacturing processes, management of supply chains and the creation of innovative sales and marketing strategies.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content